Company news: IMS, SDI and inVentiv Health

Share this article:
IMS said global spending on medicine will slow over the next five years to 3%-6% reflecting slowing growth in developed markets due to patent losses and policy changes – compared to a CAGR of 6.2% for the past five years. The data firm cited lower spending growth in the US, the continuing impact of patent expiries and belt-tightening as factors in the slowdown, offset by continued strong growth in emerging markets like Brazil, Russia, India and China, whose collective spending will become the second largest behind the US, surpassing Europe as a profit center for pharmas. 
 
SDI's Pollen.com launched an allergy alert app for Ford's dashboard SYNC system, aimed at reducing driver distractions. The app offers one-day alerts and four-day location-specific forecasts on allergy, asthma, cold and cough, along with UV sensitivity. 
 
InVentiv Health is buying contract research organization PharmaNet Development Group. It's the firm's second CRO investment since January.
Share this article:

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.